Genmab A/S (NASDAQ:GMAB) Sets New 1-Year High - Still a Buy?

Key Points

• Genmab A/S reached a new 52-week high at $27.86 and has a current trading price of $27.77, with significant trading volume.
• Analysts have mixed ratings for Genmab, with a consensus price target of $37.60 and most recent upgrades reflecting a positive outlook on the stock.
• Institutional ownership of Genmab A/S currently stands at 7.07%, with several hedge funds dramatically increasing their holdings in recent quarters.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as $27.86 and last traded at $27.77, with a volume of 46561 shares traded. The stock had previously closed at $27.54.

Analysts Set New Price Targets

GMAB has been the subject of several recent analyst reports. Wall Street Zen raised shares of Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Zacks Research lowered shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. HC Wainwright lifted their price objective on shares of Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Finally, Truist Financial lifted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $39.25.

Genmab A/S Price Performance

The firm has a market capitalization of $17.85 billion, a P/E ratio of 13.98, a P/E/G ratio of 1.67 and a beta of 0.93. The firm has a 50-day moving average price of $23.55 and a two-hundred day moving average price of $21.64.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The business had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. Sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock valued at $33,000 after acquiring an additional 440 shares in the last quarter. CWM LLC raised its holdings in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company's stock valued at $37,000 after acquiring an additional 603 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after acquiring an additional 1,070 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company's stock valued at $44,000 after acquiring an additional 1,174 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.